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CObjectives: The emergence and spread of antimicrobial resistance is
still an unresolved problem worldwide. Recent evidence shows cor-
relations between the volume of broad-spectrum antibiotics used in
the hospital setting and the incidence of multidrug-resistant bacteria.
According to this dynamic relationship, loss of antibiotic activity can be
modeled as a negative externality of antibiotic consumption.
Methods: The present study proposes to present an economic model
describing the probability of antibiotic treatment failure as a function
of antimicrobial use and alcohol-based hand-rub use. Furthermore, the
results of recently conducted time-series analyses and cost-of-illness
studies are applied to the model to determine the externalities of an-
tibiotic consumption and alcohol-based hand-rub use with respect to
the costs of hospital-acquired infections.Results: According to our cal-
culations, the consumption of third-generation cephalosporins and
fluoroquinolones is associated with the highest negative externalities O
repor
enera
al So
doi:10.1016/j.jval.2011.09.005€143 and €101, respectively) because their use has been shown to be
ssociatedwithmost types of hospital-acquired infections. In contrast,
he use of alcohol-based hand-rub solution for hand disinfection is
ssociatedwith a positive externality of 41 cents per single disinfection
f the hands. Conclusions: The externalities presented in this work
epresent a possible application of cost-of-illness data to quantify the
mpact of antibiotic use on antimicrobial resistance. In addition, the
esults indicate that most economic research on the topic is biased in
ssuming the overall use of antibiotics to be responsible for the spread
f antimicrobial resistance.
eywords: antibiotic resistance, antibiotic use, externality, hospital-
cquired infections.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The emergence and spread of antimicrobial resistance (AMR) is
still an unresolved problem worldwide. Hospital-acquired infec-
tions caused by multidrug-resistant bacteria impose a substantial
financial burden on the health-care system through exacerbation
or prolongation of illness and subsequent in-hospital treatment
[1–3]. The economic analysis of the phenomenon of infectious dis-
eases is motivated not only by their economic impact but also by
the question of how best to design and allocate the resources of
public health programs of prevention and treatment. Despite their
common use of modern statistics and mathematical modeling,
rarely have epidemiologists and economists collaborated to un-
derstand how diseases evolve and spread [4].
From a public health perspective, the effectiveness of using
antibiotic agents in hospital settings may be seen as a natural
resource that is 1) protected by the infection control practices im-
plemented to prevent cross-transmission of resistant bacteria and
2) exploited by the use of antibiotics [5]. Antibiotic use gives resis-
tant bacterial strains a comparative advantage to spread, resulting
in a direct correlation between the volume of antibiotic consump-
tion and the spread of resistance in hospital settings.
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Published by Elsevier Inc.Economic studies have used this biological background to argue
that it is within the interests of antibiotic suppliers holding property
rights to conserve the effectiveness of their antimicrobial agents [6],
or even that themonopolistic supply of antibiotics promotes conser-
vation of antibiotic effectiveness compared with the case of perfect
competition [7]. Another approach models the effectiveness of anti-
biotics as anexhaustible resource that doesnot recover effectiveness
after periods of antibiotic stewardship [8]. From this perspective, an-
tibiotic effectiveness always declines; thus, the optimal solution in
this case would be to use the antibiotic with the greatest effective-
ness first [8]. In short, all these studies are based on the basic ap-
proach that considers the cost of resistance to be a negative exter-
nality of antibiotic use [9–15]. Accordingly, the conclusions are that
the problem of AMR should be counteracted on the macro level by
reducing the overall antibiotic consumptionwith policy options that
are traditionally associated with environmental economics such as
regulation, permits, and charges [6,7,10,13].
On the other hand, recent epidemiological studies have made
advances in modeling hospital-wide dynamics between antibiotic
use, hand disinfection, bed occupancy rates, and the incidence of
hospital-acquired infections due to different pathogens. The statisti-
cal technique of time-series analysis has especially proven to be a
powerful tool to determine the relationship between antibiotic use
t.
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88 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 7 – 9 3and theoccurrenceandspreadofmethicillin-resistant Staphylococcus
aureaus (MRSA), which is themost frequently identified antimicrobial-
resistant pathogen in hospital settings [16–18]. Some studies also in-
clude the use of antiseptic hand rub in their analysis [19–22]. This
gives amore completepicture of thedynamics of resistance, because
the influence of both selective pressure and the transmission of re-
sistant strains is analyzed. Interestingly, the overall consumption of
antibiotics was not shown to have any impact on the incidence of
hospital-acquired infections in the above-mentioned studies. In-
stead, only some classes of broad-spectrum antimicrobials had a
stimulating effect on the spread of hospital-acquired infections. The
same is true for theoutpatient sector,where theavailable evidence is
not as clear as in the hospital setting, but indicates that some classes
of broad-spectrum antimicrobials might be identified as promoting
the spread of resistant pathogens [23–25].
Accordingly, most economic research on the topic is biased in
ssuming that the overall use of antibiotics is responsible for the
pread of infections. In fact, the detailedmodeling approaches avail-
ble at the hospital level show that the spread of infectious diseases
an be counteracted by reducing the use of some clearly identified
lasses of broad-spectrum antimicrobials. The consequences of this
pecific information are far reaching because it means that, at least
n the hospital setting, it is not generally necessary to avoid using
ntibiotics. Instead, an efficient situation is given if the externalities
orbroad-spectrumantimicrobialsare internalized in thephysicians’
ationale for prescribing antimicrobials.
In the present work, a simple economic model is presented to
etermine the external effects of using broad-spectrumantimicrobi-
ls and alcohol-based hand rub with respect to the emergence of
MR [15]. Next, the model will be applied to the results of recently
onducted cost-of-illness (COI) studies and the results of the above-
entioned time-series analyses conducted at University Medical
enter Freiburg (UMCF), a tertiary care teaching hospital in southern
ermany, to determine the externalities of antibiotic consumption,
lcohol-based hand-rub use for hand disinfection, and high bed oc-
upancy rates from the perspective of a hospital.
Modeling the externality
The following model is based on Phelps [12], whose model has also
been applied by others [10,11]. There are some differences, however,
with regard to the following aspects: Phelps aimed to estimate the
externality of antibiotic use for all antibiotics delivered in the United
States within 1 year and, accordingly, made crude estimates regard-
ing theextra costsof resistanceand thegeneral relationshipbetween
antibiotic use and resistance. In the work presented here, however,
the focus is more specific, focusing on in-hospital antibiotic treat-
ment and the clearly defined adverse effect of hospital-acquired in-
fections. Inaddition, therehavebeen recentproceedings inmodeling
the relationship between antibiotic use and the adverse health out-
comes in the setting of a single hospital [15].
In hospital settings, we may assume the probability of antibi-
otic treatment failure R(q, h) as a function of the use of antimicro-
bial q and alcohol-based hand-rub use h [15]. Let the cost of an
infection be equal to C0  V, with C0 representing the cost of
reating susceptible infections and V being the additional cost of
reatment failure. From the perspective of a hospital, the expecta-
ions regarding the cost of treating a single infection are equal to
(q, h)C0R(q, h)V (1)
Accordingly, for small variations, we obtain the following formula:
CV
R(q, h)
q
dqV
R(q, h)
h
d h (2)
Becausewe are interested in the externality of a single unit of q
nd h, we may assume dq dh 1. Furthermore, the first and last dterms of Equation 2 can bemultiplied by
R
q
q
R
and
R
h
h
R
, respectively.
Because
Rq, h
q
q
R
and
Rq, h
h
h
R
represent elasticities, we may re-
rrange Equation 2 to
C
R
q
qV
R
h
hV (3)
here j (i  q, h) stands for the elasticities of the dose–response
relationships.
With the perspective on the total amount of infections T, we
may follow the steps above to define changes in the expected cost
of treating resistant infections, which are defined as a result of a
unit change in antibiotic use and alcohol-based hand-rub use:
d(TC)
TR
q
qV
TR
h
hV (4)
where TRmay also be interpreted as the incidence of treatment
failure due to a resistant organism.
The empirical background
The impact of antibiotic consumption and alcohol-based hand-
rub use on the incidence of hospital-acquired infections caused
by MRSA was analyzed in a recent study at UMCF [21]. For this
purpose, a multivariate model was built by using a polynomial
distributed lag modeling approach. In a first step, different
classes of antimicrobials were analyzed by using univariate or-
dinary least-square regressions to select the independent vari-
ables for inclusion in the model and to identify lag structures
[21,22]. The estimated multivariate model (R2  0.66) included
ix statistically significant independent variables and can be
escribed as follows:
og(HA-MRSAt)2GC log(2GCt1)
i3
4
3GC,i log(3GCti)
FQ log(FQt4)  LIN log(LINt2)
i3
7
AHD,i log(AHDti)
 CA-MRSA log(CA-MRSAt)ut (5)
here HA-MRSA stands for the number of nosocomial MRSA in-
ections, 2GC for second-generation cephalosporins, 3GC for third-
eneration cephalosporins, FQ for fluoroquinolones, LIN for linco-
amides, AHD for alcohol-based hand rub, and CA-MRSA for the
umber of patients admitted with MRSA. All input series are ex-
ressed in values per 1000 patient-days [21].
As shown in Table 1, positive coefficientswere estimated for all
ntimicrobial classes integrated into the multivariate model
Equation 5). This shows that temporal increases/decreases in the
olume of antimicrobial consumption are followed by a temporal
ncrease/decrease in the incidence of hospital-acquired MRSA in-
ection. Because all the variableswere normalized because of loga-
ithmical transformation, all coefficients estimated for antimicro-
ial consumption equal the average percentage change in the
ncidence of hospital-acquired MRSA infections after a 1% change
n the use of the selected antimicrobials. Conversely, the algebraic
ign of the coefficient estimated for the use of alcohol-based hand
ubwas negative, which shows that a temporal increase in the use
f alcohol-based hand rub is followed by a temporal decrease in
he incidence of hospital-acquired MRSA infections.
For proof of the hospital-wide cause–effect chain assumed in
he model, an identical model was built by using the incidence of
lostridium difficile–associated diarrhea (CDAD) as the dependent
ariable [21]. For CDAD, themultivariate analysis (R2 0.55) can be
escribed as follows:
al
p
l
t
o
a
r
t
w
p
i
t
p
w
r
t

d
t
p
b
k
u
l
89V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 7 – 9 3log(Cdifft)
i0
1
3GC,i log(3GCti)
i2
3
FQ,i log(FQti)
 
i2
3
MAC,i log(MACti)ut (6)
where Cdiff stands for the number of CDAD cases, 3GC for third-
generation cephalosporins, FQ for fluoroquinolones, and MAC for
macrolides. Again, all input series are expressed in values per 1000
patient-days [21]. As shown in Table 1, positive coefficients are
estimated for all antimicrobial classes integrated into the multi-
variate model (Equation 6), showing that greater use of third-gen-
eration cephalosporins, fluoroquinolones, and/or macrolides was
followed by a higher incidence of CDAD. A correlation with alco-
hol-based hand-rub use was not detected, which is reasonable
because CDAD is caused by spores that tend to be relatively resis-
tant to the antiseptic effects of alcohol [21].
In a second study [22], the methodology presented above was
applied to identify the impact of antibiotic consumption and alco-
hol-based hand-rub use on the incidence of hospital-acquired
strains of extended-spectrum -lactamase (ESBL)-producing bac-
teria, another serious multidrug-resistant pathogen. The multi-
variate analysis (R2 0.75) presented in the study can be described
s follows:
og(HA-ESBLt)3GC log(3GCt3)FQ log(FQt1)
 
i3
4
AHD,i log(AHDti)CA-ESBL log(CA-ESBLt)ut (7)
where HA-ESBL stands for the number of nosocomial ESBL cases,
3GC for third-generation cephalosporins, FQ for fluoroquinolones,
AHD for alcohol-based hand rub, and CA-ESBL for the number of
patients admitted with ESBL. Again, all input series are expressed
in values per 1000 patient-days [22].
The results of the multivariate analysis (Equation 7) are sum-
marized in Table 1, showing that the use of alcohol-based hand
rub for hand disinfection had a significant influence on the inci-
dence of ESBL. A higher volume of alcohol-based hand-rub use
was subsequently associated with a lower incidence of ESBL-pro-
ducing strains. In addition, the model showed that temporal in-
crease in the use of third-generation cephalosporins and fluoro-
quinolones was followed by temporal variations in the incidence
of nosocomial ESBL. Furthermore, the incidence of patients admit-
ted with ESBL was also shown to have an influence on the inci-
dence of nosocomial ESBL. The analysis shows that a higher inci-
dence of patients admitted with ESBL was followed by a higher
incidence of nosocomial ESBL. The final model explained 75% of
Table 1 – Elasticities that represent the impact of antibiotic
CDAD, and ESBL at University Medical Center Freiburg.
Independent variable MRSA
Coefficient Elasticit
Alcohol-based hand rub 5.37* 5.37
Second-generation cephalosporins 1.41† 1.41
Third-generation cephalosporins 1.03‡ 1.03
Macrolides — —
Lincosamides 0.42† 0.42
Fluoroquinolones 1.12† 1.12
The MRSA incidence was defined as the number of MRSA infections
The ESBL incidence was defined as the number of ESBL infections and
patient-days. The CDAD incidence was defined as the number of CD
CDAD, Clostridium difficile–associated diarrhea; ESBL, extended-spectr
* Significant at the 1% level.
† Significant at the 5% level.
‡ Significant at the 10% level.the monthly variations in the incidence of nosocomial ESBL.Other studies [26,27] also conducted at UMCF analyzed the im-
act of bed occupancy rates, turnover intervals, and the average
ength of hospital stay on the spread ofMRSA, ESBL, andCDAD. For
his purpose, threemultivariate time-series analyses were carried
ut with the incidences of nosocomial MRSA, nosocomial ESBL,
nd CDAD as dependent variables. Time series of bed occupancy
ates, turnover intervals, and the average length of stay were
ested for inclusion in the models as independent variables. We
ere able to show in the final multivariate models that bed occu-
ancy rates in general wards are positively correlated with the
ncidence of hospital-acquired MRSA and the incidence of hospi-
al-acquired ESBL. Themultivariate models demonstrate the tem-
oral relationships between the bed occupancy rates on general
ards and the incidence of nosocomial MRSA (P  0.001), nosoco-
mial ESBL (P 0.042), andCDAD (P 0.001). Similarly, the temporal
elationships between the monthly average length of stay in in-
ensive care units (ICUs) and the incidence of nosocomial MRSA (P
0.001), nosocomial ESBL (P  0.019), and CDAD (P  0.001) are
emonstrated.
Overall, the three pathogens MRSA, ESBL, and CDAD represent
he majority of AMR pathogens that are included in surveillance
rograms in German hospitals. With respect to the relationship
etween antimicrobial use and the emergence of resistance, these
inds of pathogens are well observed and the impact of antibiotic
se on the spread of these pathogenswas shown on the individual
evel as well as on the level of an entire hospital [18–22,28–31].
Transformation of results
The dose–response relationship between antibiotic consumption
and the emergence of resistance was first described in 1989 by
Phelps [12], who defined the term as “the percentage change in the
probability of an organism being resistant following a 1% change
in the level of antibiotic use”. In economic science, the time-series
analysis is used extensively for the analysis of economic relation-
ships (econometrics). In this context, the dose–response rate is
termed elasticity and can easily be deduced from the coefficients
estimated by time-series analyses [32].
In the time-series analyses presented here, in which a log-lin-
ear modeling approach was used for the estimation of the multi-
variate model, the elasticity of the infection rate IR,i is defined as
IR,q
 log IR(q)
 log q
(8)
d alcohol-based hand-rub use on the incidences of MRSA,
CDAD ESBL
Coefficient Elasticity Coefficient Elasticity
— — 6.73* 6.73
— — — —
1.41* 1.41 1.98† 1.98
1.19* 1.19 — —
— — — —
1.01‡ 1.01 4.43* 4.43
ere detected more than 48 h after admission per 1000 patient-days.
izations that were detectedmore than 48 h after admission per 1000
fections or colonizations per 1000 patient-days.
-lactamase; MRSA, methicillin-resistant Staphylococcus aureaus.- an
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 log IR(h)
 log h
(9)
here IR(q) (IR(h)) stands for the infection rate, which is a function
f the consumption of q(h). The variables q and h represent the
ndependent variables used in the time-series analysis, that is, a
eries of the consumption of a class of antimicrobials or the hand
isinfection series. In this case, all estimated coefficients may be
nterpreted as dose–response rates without transformation.
Where nonlogarithmically transformed variables were used in
he multivariate model, the elasticity IR,i is defined as
IR,q
IR(q)
q
q
IR(q)
(10)
or
IR,h
IR(h)
h
h
IR(h)
(11)
Following this concept, the estimated coefficients can be
ransformed into elasticities, thus facilitating comparisons be-
ween different study settings. First, estimated coefficients are
nserted in the first fraction of Equation 10 (IRq⁄q). Second,
he monthly average of the proportion q⁄IRq is to be inserted in
he second fraction.
See Table 1 for an overview of the different elasticities with
regard to the incidences of MRSA, CDAD, and ESBL at UMCF. Table
2 shows the elasticities that represent the impact of bed occu-
pancy rates on general wards and the average length of stay in ICU
settings on the incidences of MRSA, CDAD, and ESBL at UMCF.
Results
Table 1 shows elasticities of the infection rate with respect to an-
tibiotic use (or alcohol-based hand-rub use). This is inconsistent
with the approach explained above where the elasticity was de-
fined as percent changes in the probability of antibiotic treatment
failure R(q, h) due to changes in antibiotic (or alcohol-based hand-
rub) use: q
Rq, h
q
q
R
. However, this problem can be resolved by
mposing the assumption that antibiotic treatment failures occur
nly because of MDR organisms. Accordingly, we assume the in-
idence of antibiotic treatment failure (TR) to be equal to the num-
er of hospital-acquired infections.
According to the elasticities shown in Table 1, the use of anti-
iotics such as fluoroquinolones and third-generation cephalo-
porins promotes the emergence and spread of MRSA, ESBL, and
DAD.We know from the literature that patientswith an infection
Table 2 – Elasticities that represent the impact of the bed o
stay in ICU settings on the incidences of MRSA, CDAD, and
Independent variable MRSA
Coefficient q/IR(Q) Elastic
Bed occupancy, general wards 0.56* 0.78/0.15 2.91
Length of stay, ICUs 0.18* 2.9/0.15 3.48
The MRSA incidence was defined as the number of MRSA infections
1000 patient-days. The ESBL incidence was defined as the number of
admission per 1000 patient-days. The CDAD incidence was defined a
CDAD, Clostridium difficile–associated diarrhea; ESBL, extended-spec
Staphylococcus aureaus.
* Significant at the 1% level.
† Significant at the 5% level.aused by those pathogens impose an additional cost of hospital-
zation. The additional cost of an MRSA patient, for instance, was
ecently determined in amulticenter study conducted in Germany
mean additional costs in comparison to an appropriate control
roup: €8,198) [33]. The study took various types of MRSA infec-
tions into account, which is an important detail because all types
of MRSA infections were analyzed in the time-series analysis ex-
plained above [21]. Also, the results are in line with the interna-
tional literature. Recent literature reviews report the attributable
costs (all determined in comparison to an appropriate control
group) of MRSA-related bacteremias (mean attributable costs ac-
cording to three studies: US$6,916), ventilator-associated pneu-
monia (mean attributable costs according to one study: US$7,731),
or surgical infections (mean attributable costs according to one
study: US$13,901) [2,34].
The same is true for CDAD, where an additional cost of €7147 per
CDAD case was recently determined in a German teaching hospital
[35]. This result is also in accordance with data from different inter-
national studies: Spencer [36], for instance, estimated extra costs of
£4000 per CDAD case, whereas Wilcox et al. [37] determined extra
costs of US$8130 per CDAD case. All additional costs were deter-
mined in comparison to an appropriate control group.
The additional cost of an ESBL infection, however, was not deter-
mined previously in a German setting. Furthermore, the interna-
tional literature on this topic is sparse [38]: there are only two studies
that provide valid estimates of the additional cost of ESBL infection,
with results ranging between US$9,620 and US$16,450, all of which
were determined in comparison to an appropriate control group
[39,40]. To measure the externality, we may assume a conservative
estimate of €5,000 per ESBL infection in German teaching hospitals.
The calculations shown in Table 3 demonstrate the extent of
the externality of antibiotic consumption from promoting resis-
tance. According to the presented calculations, there is a sub-
stantial negative externality associated in particular with the
use of third-generation cephalosporins and fluoroquinolones
(€143 and €101, respectively) because their use was shown to
influence the incidences of MRSA, CDAD, and ESBL. For compar-
ison, the use of third-generation cephalosporins reflects only
7% of all antimicrobials used at UMCF during the study period
(2003–2007) [21]. Fluoroquinolone use equates to around 11%
[21]. In contrast, the use of second-generation cephalosporins
imposes a far lower externality (€4.75) but makes up approxi-
mately 30% of all antimicrobials used between 2003 and 2007.
Furthermore, the use of alcohol-based hand-rub solution for
hand disinfection was shown to be associated with a positive
externality of €6124 from protecting people from MRSA-related
infections and a further positive externality of €7664 from pro-
tecting people from ESBL-related infections. If we assume that a
ancy rates in general wards and the average length of
L at University Medical Center Freiburg.
CDAD ESBL
Coefficient q/IR(Q) Elasticity Coefficient Elasticity
1.21* 0.78/0.50 1.89 3.39† 3.39
0.29* 2.9/0.50 1.68 2.92† 2.92
olonizations that were detected more than 48 h after admission per
infections and colonizations that were detected more than 48 h after
number of CDAD infections or colonizations per 1000 patient-days.
-lactamase; ICU, intensive care unit; MRSA, methicillin-resistantccup
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91V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 7 – 9 3single disinfection of the hands is equivalent to the use of 3 ml
of alcohol-based hand-rub solution, every single hand rub saves
€0.18 in potential costs incurred by MRSA-related infections and
another €0.23 in potential costs incurred by ESBL-related infec-
ions. These figures are all the more interesting if we take into
ccount that at UMCF the average price of hand-rub solution is
3.70/L, which equates to a price of 1 cent per hand rub.
The question remains how the correlations between the bed
ccupancy rates and the different incidences may be interpreted
roman economic perspective. During the study period, amonthly
ean of 43,319 bed-days was available, of which, on average,
3,619 were occupied. If, for instance, an additional bed was occu-
ied for 24 hours, the bed occupancy rate on general wards would
ncrease by an average of 0.000023085. To determine the external-
ty of this additionally occupied bed, Equation 4 may simply be
odified to dTC  TR ⁄ boboV and the result multiplied with
he impact of an additionally occupied bed on the bed occupancy
ate (0.000023085). Accordingly, if we apply the values shown in
ables 2 and 3, we obtain a negative externality of €0.11 in poten-
ial costs incurred by MRSA-related infections, €0.08 in potential
osts incurred by ESBL-related infections, and another €0.20 in
otential costs incurred by CDAD. In summary, one additionally
ccupied bed influences the bed occupancy rate and thus influ-
nces the number of hospital-acquired infections, but the overall
mpact per occupied bed is extremely low (39 cents per occupied
ed, which is a negligible amount of money compared with the
verall per diem cost of hospitalization).
Conclusions
The study presented here is based on the theoretical concept of
describing AMR as a negative externality of antibiotic use previ-
ously described in various studies [1,9,11,13–15,41].
A major strength of the analysis was that many of the param-
eters collected came from a single source, namely, a teaching hos-
pital in Germany. The estimates presented are of course crude and
should not be interpreted as the exact costs expected but rather as
a rough estimate of an externality in hospital settings. In pecuni-
ary terms, the individual externalities are small compared with
the daily cost of hospitalization; however, they are significant
compared with the direct cost of an antibiotic.
Of course, there are several limitations regarding the robust-
ness of the different parameters used in the analysis. For instance,
the elasticities were previously determined in other settings
[19,20,28]. As stated above, two other studies determined elastici-
ties of 0.32 and 0.55, respectively, between third-generation ceph-
alosporin use andMRSA [42], which is substantially lower than the
elasticity determined at UMCF. This is also true for CDAD, where a
study in Belfast calculated elasticities that were much lower than
those at UMCF [28,43]. In addition, a main assumption in the anal-
ysis was that the use of antibiotics directly influences the number
of hospital-acquired infections. This may be assumed for MRSA,
where a time-series analysis was performed with the incidence of
nosocomial MRSA infections as dependent variable. For ESBL,
however, the time-series analysis used the incidence of nosoco-
mial ESBL infections and colonizations as dependent variable,
which makes sense, because antibiotic use may also affect the
number of patients colonized with these pathogens; however,
from the perspective of the cost of resistance only the patients
infected are of major interest. A more general limitation relies in
the assumption that antibiotic treatment failures occur only be-
cause ofmultidrug-resistant organisms:Wemay imagine the case
that an antibiotic treatment failure occurs because of other rea-
sons, leading coincidentally to an infection due to multidrug-re-
sistant organisms.
Another question is whether the cost figures discussed above
are adequate for the analyses. As stated above, there are no cost
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92 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 7 – 9 3figures of reference for ESBL determined in a German setting; how-
ever, one study conducted in a German teaching hospital shows
that there is no excess length of hospital stay for patients with
ESBL-related urinary tract or wound infections but only for pa-
tients with respiratory tract and bloodstream infections.
To evaluate the generalizability of the results, several aspects
have to be taken into account: First of all, most of the parameters
were determined in a single setting, a German teaching hospital.
The elasticities, for instance,may behospital specific in their exact
amount, depending of the baseline levels of resistance and antibi-
otic use. Accordingly, there may be a need to determine a number
of hospital-specific parameters (TR, q, h, and ). With respect to
fluoroquinolone consumption and the incidence of MRSA, for in-
stance, the ratio TR/q equals 0.0012179 and the elasticity  equals
1.12 (see Table 3), leading to the product TR⁄q 0.001364. We
may now compare this product with comparable results deter-
mined in other settings previously. The coefficients estimated in
time-series analyses conducted in Belfast and Geneva can be
transformed into elasticities of 0.27 and 0.36, respectively [42],
which is about one-third of the elasticity used in the present anal-
ysis [19,20]. The different levels of fluoroquinolone consumption q
(5.03 defined daily doses (DDDs) per 100 bed-days in Belfast and
5.41 DDDs per 100 patient-days in Geneva) and especially the
higher MRSA-incidence TR (0.09 MRSA cases per 100 bed-days in
Belfast and 0.15MRSA cases per 100 patient-days in Geneva), how-
ever, result in a much higher measure for the product TR⁄q. In
detail, the product TR⁄q equals 0.004831 in Belfast and 0.009981
in Geneva [19,20], which is far higher than the product determined
at UMCF. This indicates that the measures TR, q, h, and  can and
should be adjusted for the respective setting.
The cost figures, however, have been shown to be better gen-
eralizable because they were determined in multiple settings and
have been shown to be comparable in their dimension even when
contrasting cost figures were determined in different countries.
Please note that the selection of the cost figures might be used for
changing the perspective of the analysis.
Further limitations of the analysis are the use of a purely ac-
counting formula that does not include behavioral relationships
as shown in other studies [11,12]. In addition, the focus of this
work was only on the cost of resistance due to treatment without
taking into account the benefits of antibiotic use.
Finally, the present work shows that the cost of AMR due to
antibiotic use should be taken into account in the economic anal-
ysis of health-care costs. An example for inclusion of the external-
ity of antibiotic use in a study is provided by Salkind and Wright
[41], who calculated the financial burden of the prescription of
antibiotics for viral pharyngitis in ambulatory care. The study ob-
served two main outcomes: 1) direct expenditures for pharyngitis
management in ambulatory care and 2) and the externality of an-
tibiotic use with respect to the cost consequences of resistant
Streptococcus pneumoniae infections. For simplicity, the cost data of
resistant S. pneumoniae infections were adopted from another pre-
viously published study, and the elasticity between antibiotic use
and resistant S. pneumoniae infections was crudely estimated (
.1–1.0) because of the lack of available data.
In recent years, a number of time-series analyses conducted in
ospital settings have determined valid elasticities for the most
roblematic hospital-specific pathogens such as MRSA, ESBL-pro-
ucing strains, vancomycin-resistant Enterococcus, and Clostridium
ifficile [18–22,44]. Furthermore, a number of studies have deter-
ined the financial burden of different hospital-acquired infec-
ions due to resistant pathogens [2,3,34].
More than four decades ago, Rice [45] was the first person to
escribe the methodology of COI studies. In general, the aim of a
OI study is to identify and measure all the costs of a particular
isease, including the direct, indirect, and intangible costs [46,47].
n recent years, however, the economic value of COI studies as anid to decision makers has been questioned [48,49]. For instance,
he economist Martin Feldstein [50] once disparaged COI studies
s a method for “calculating the benefits of unattainable goals”.
his criticism is still present in the current literature, where it is
laimed that cost savings of either fully or partially preventing a
iven disease are to a large extent illusory, and COI results give
nly a static picture of costs that are not explained by specific
actors [46,51,52]. Others have responded that COI studies could be
olicy-relevant if COI data were combined with other data for fur-
her economic evaluation [53,54]. That was also the main chal-
enge of the present analysis: We attempted to relate the costs of
n infection to specific factors that have been shown to influence
he incidence of hospital-acquired infections.
As mentioned above, most economic research on the topic is
iased in assuming overall antibiotic use to be responsible for the
pread of infections. In fact, the analysis shows that the economic
ilemma that describes the gains from the overuse of antibiotics
s private, while the losses are public, does not apply to antibiotic
se in general but only to the use of some specific classes of broad-
pectrum antibiotics. This is underlined by the fact that the use of
ntimicrobials with the highest externalities accounted for no
ore than 18% of all antibiotics used at UMCF between 2003 and
007.
The consequences of this specific information are far reaching
nd serious because it means that the degree of substitutability
etween broad- and narrow-spectrum antibiotics is a crucial pa-
ameter for appropriate modeling of the phenomenon of resis-
ance. Some studies show significant own- and cross-price elas-
icities of demand for antibiotics [55–59], which also indicates a
ubstitutability between different antimicrobial agents. Unfortu-
ately, most of these estimates are based on outpatient data and
he only study using wholesale data—which does not distinguish
etween in-hospital and outpatient demand—determines cross-
rice elasticities for different agents of the same class of antibiot-
cs only [56].
In summary, the externality presented in this work represents
possible application of COI data to quantify the impact of anti-
iotic use on AMR. The application of recent epidemiological re-
ults in a simple economicmodel shows that modeling the conse-
uences of AMR as an externality of antibiotic use is appropriate
or some classes of broad-spectrum antimicrobials only. In addi-
ion, the results of the analysismay be used for further COI studies
s a rough estimate of the indirect costs of in-hospital antibiotic
se.
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